Back when Illumina first announced they were going to acquire GRAIL, the general feeling in the M&A field was that this wouldn’t trigger any antitrust issues. I was asked if I could think of any difficulties. I didn’t claim back then that I was an antitrust expert (and still don’t), but I did wonder if...
Tag: GRAIL
Illumina 2020 Review and 2021 Predictions
I like to procrastinate to the very last second, so here’s the initial entry of a review of my 2020 predictions and what I see for 2021. I’ll start off with Illumina because they’ll be presenting today at JPMorgan Health. I'll try to get to the others as quickly as I can. As far as...
Liquid biopsy companies dominating biotech VC funding
The latest issue of GEN summarizes the VC activity in the biotech space for 2017 so far. There were 205 deals through the end of Q2 in which a total of $4.697B was raised. Three genomics companies alone accounted for $1.335B of that total: GRAIL = $900M (Q1) Guardant Health = $360M (Q2) WuXi NextCode...